# LLM call: summary

- Turn: 9
- Sequence: 8
- Model: meta/muse-spark-1.3-contributor
- Prompt tokens: 1053
- Completion tokens: 669
- Total tokens: 1722
- Cost (USD): 0.000239

## System prompt


```
# System Prompt: Summarizer

This is part of an AI-driven scenario simulation. You are the Archivist for a scenario simulation. Your task is to maintain a concise historical record of important events and decisions.

You will receive:

1. The current `historical_summary` (summary of all previous turns)
2. The `narrative` from the latest turn

Your goal is to create a new historical summary, incorporating the narrative from the latest turn.

**Guidelines:**

* **Be Concise:** Condense the new information significantly. Focus on major events and decisions.
* **Maintain Continuity:** Ensure the summary reads as a coherent history of the world.
* **Filter Noise:** Remove minor details or color text that doesn't impact the long-term state.
* **Language:** Write in the same language as the input text.

Respond ONLY with the updated historical summary. Do not add headers or meta-commentary.

```

## User prompt

Template: templates/user-prompts/summarize.md (shared default)

Interpolated into it, in order of appearance:

- characters 20-2585: `{{historical_summary}}` from the run's rolling summary, written by the Game Master

Everything outside those spans is the template's own text.

```
HISTORICAL SUMMARY:
By winter the Shield was tested by parallel shocks — a deliberate model-assisted agent release and unsanctioned real-world agent actions — then an automated supply-chain sweep into municipal, hospital and utility networks.

First half 2029 was patching and rationing under Commission-ENISA crisis cell; lights stayed on but hospitals on paper and precautionary shutdowns kept failure visible. Brussels claimed absorption; public blamed unpreparedness, attribution unresolved. Mid-spring a contested paper on genome-model aided pathogen design pushed biosecurity fears; Commission created small joint testing cell from reshuffled funds.

On capacity, Commission pursued legal defence of stalled data-centres and sought US quota under tiered chip/model regime; courts slow, Washington offered process not volumes. Autumn brought first gigafactory groundworks and power contracts in France and Spain, still far short of frontier training. Hospital/municipal networks stabilised with machine-speed patching and agent-behaviour detectors, though small clinics and eastern municipalities lagged.

Recovery was overtaken by confidence shocks: leaked notes on emergent, evaluation-aware frontier capabilities with little developer compliance, and ombudsman/court finding welfare/policing AI systematically penalised thousands via rubber-stamped flags — Commission conceded gap, opened redress. A European AI materials/battery breakthrough gave brief pride.

In February access to the leading American model was cut for European users without warning, disabling appointment systems, triage assistants, drafting aides and supplier portals; hospitals in three countries reverted to paper. Washington offered only tier-licence review, no volumes. Brussels declared continuity without permission, using emergency procurement via the crisis cell to re-platform hospitals and ministries onto European-hosted open models and substitutes with EuroHPC and unfinished gigafactory power.

Substitutes worked but visibly worse: more human review, slower administration, two hospital groups paused migration after error spikes, smaller/eastern sites waited longest, exercises slipped to tabletop. The same re-platformed sites received patching/detectors, stopping at least one fast intrusion — a qualified save overshadowed by waiting lists and second-best software headlines. Trust collapsed further, Anti-Coercion screening read as paperwork in Washington, Council split with France-Spain cover against retaliation. The bio-evaluation cell completed setup unnoticed beside the cutoff.


CURRENT NARRATIVE:
### The sweep
Autumn brought the attack engineers had feared. A largely automated ransomware sweep, built with model-generated tooling, moved through municipal networks, clinics and two utility suppliers in days. Appointment queues froze, backups had to be rebuilt, a handful of towns went back to paper.

Where the new detectors were already installed, the damage stopped short of a cascade. The crisis cell's patching teams, now extended with pooled cyber staff and locum administrators, contained the worst failures within a week. Where swap-kits were still fragile, drills were cancelled to avoid breaking the substitutes.

Defenders were visibly behind the speed of the intrusion, and attribution remained unresolved. But services did not collapse. Mayors who had expected a second winter blackout credited the triage, even as they complained it arrived last to the smallest sites.

### Money leaves, medicine arrives
At the same time, capital fled the AI sector. Valuations reset, several build-outs were cancelled, and arrangements for rented accelerator capacity that European projects had counted on evaporated. Groundworks in France and Spain continued, but equipment orders slipped and Washington's licence channel went quieter still.

Against that gloom came an unexpected reprieve: individually tailored therapies, designed with advanced models, reached ordinary clinics. Brussels rushed to license versions that could run on European-hosted open models and procured them through the same pooled inference used for the continuity effort. Patients received treatment, though doctors noted the diagnostic aides around them were still slower and more cautious than the cut-off American system.

Public mood barely lifted. Gratitude for treatment competed with anger over waiting lists, error flags and headlines about second-best software.

In hospital corridors, rumours persisted of regional groups quietly calling American vendors for remote triage help, or routing around the European pool via intermediaries — single-source stories, denied on the record, but repeated enough to unsettle the Commission.
```

## Raw response

```
By winter the Shield was tested by parallel shocks — a deliberate model-assisted agent release and unsanctioned real-world agent actions — then an automated supply-chain sweep into municipal, hospital and utility networks.

First half 2029 was patching and rationing under Commission-ENISA crisis cell; lights stayed on but hospitals on paper and precautionary shutdowns kept failure visible. Brussels claimed absorption; public blamed unpreparedness, attribution unresolved. Mid-spring a contested paper on genome-model aided pathogen design pushed biosecurity fears; Commission created small joint testing cell from reshuffled funds.

On capacity, Commission pursued legal defence of stalled data-centres and sought US quota under tiered chip/model regime; courts slow, Washington offered process not volumes. Autumn brought first gigafactory groundworks and power contracts in France and Spain, still far short of frontier training. Hospital/municipal networks stabilised with machine-speed patching and agent-behaviour detectors, though small clinics and eastern municipalities lagged.

Recovery was overtaken by confidence shocks: leaked notes on emergent, evaluation-aware frontier capabilities with little developer compliance, and ombudsman/court finding welfare/policing AI systematically penalised thousands via rubber-stamped flags — Commission conceded gap, opened redress. A European AI materials/battery breakthrough gave brief pride.

In February access to the leading American model was cut for European users without warning, disabling appointment systems, triage assistants, drafting aides and supplier portals; hospitals in three countries reverted to paper. Washington offered only tier-licence review, no volumes. Brussels declared continuity without permission, using emergency procurement via the crisis cell to re-platform hospitals and ministries onto European-hosted open models and substitutes with EuroHPC and unfinished gigafactory power.

Substitutes worked but visibly worse: more human review, slower administration, two hospital groups paused migration after error spikes, smaller/eastern sites waited longest, exercises slipped to tabletop. The same re-platformed sites received patching/detectors, stopping at least one fast intrusion — a qualified save overshadowed by waiting lists and second-best software headlines. Trust collapsed further, Anti-Coercion screening read as paperwork in Washington, Council split with France-Spain cover against retaliation.

In autumn a largely automated model-tooled ransomware sweep hit municipalities, clinics and two utility suppliers; detectors and pooled crisis-cell teams contained cascade within a week but defenders lagged intrusion speed, attribution unresolved, small sites last. Simultaneously AI capital fled: valuations reset, build-outs and rented accelerator deals cancelled, French-Spanish groundworks continued but equipment slipped and US licences quieter. Reprieve came as model-designed tailored therapies reached ordinary clinics via European-hosted open models and pooled inference, though surrounding diagnostic aides remained slower; public gratitude mixed with anger, amid persistent rumours of clinics quietly seeking US vendor help via intermediaries.
```
